Sulbactam-enhanced cytotoxicity of doxorubicin in breast cancer cells

Sulbactam-enhanced cytotoxicity of doxorubicin in breast cancer cells

Abstract Background Multidrug resistance (MDR) is a major obstacle in breast cancer treatment. The predominant mechanism underlying MDR is an increase in the activity of adenosine triphosphate (ATP)-dependent drug efflux transporters. Sulbactam, a β-lactamase inhibitor, is generally combined with β-...

Full description

Bibliographic Details
Main Authors: Shao-hsuan Wen, Shey-chiang Su, Bo-huang Liou, Cheng-hao Lin, Kuan-rong Lee
Format: Article
Language:English
Published: BMC 2018-09-01
Series:Cancer Cell International
Subjects:
Sulbactam
Breast cancer
ABC transporters
Doxorubicin
Proteomics
Inhibitors
Online Access:http://link.springer.com/article/10.1186/s12935-018-0625-9

Internet

http://link.springer.com/article/10.1186/s12935-018-0625-9

Similar Items